VALAMIS
22.7.2021 10:02:14 CEST | Business Wire | Press release
Valamis , the global leader in digital learning technologies and workforce development, has announced the acquisition of The Working Manager (TWM), a leader in organisational performance and career mobility technology. Valamis and TWM have entered into a definitive agreement to join together and unify technologies and in-house consulting services to offer businesses an end-to-end employee experience that helps employees develop and find career opportunities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210722005023/en/
Valamis Learning Solution and TWM’s CareerBurst career platform and learning platform technologies will bring Executives, Human Resources, Learning & Development, and Talent professionals a technology and consulting solution to develop and retain employees for organisational performance. Valamis and TWM will be able to help over 3 million learners and serve a diverse global client base.
“The Working Manager’s technology, proven record of customer satisfaction, and most importantly their people, are a complete fit with Valamis’ longstanding values. With TWM’s internal career development platform, LMS, and LXP, we will enhance our current learning solutions for our customers and future customers. Together, our technology, partnership approach, and authenticity will give the market a solution that puts people first and helps customers every step of the way succeed with their business initiatives”, explained Jussi Hurskainen, CEO, Valamis.
After a long period of remote work for many employees across the world at the onset of the pandemic, many businesses have begun outlining their ‘return to the office’ plans, which has ushered in what NPR is calling the ‘Great Resignation’, as more workers in the U.S. are quitting their jobs than at any time in at least two decades. According to a LinkedIn report , 94% of employees would stay at a company longer if it invested in their careers. The acquisition and combined products and services of Valamis and TWM will provide an opportunity for employers to reduce the high cost of employee turnover and labour shortages by upskilling their employees and improving career mobility.
“At TWM our accounts managers are all former heads of L&D, we understand first-hand many of the challenges that our customers are facing. That helps us develop our software in line with those requirements but also gives us an understanding of the partnership that is required to address the rapidly changing needs of businesses. Valamis has a similar approach and company culture that will empower businesses across the U.K. and globally to build greater employee loyalty and, in the end – stronger businesses”, said Phil Purver, CEO, TWM.
About Valamis
Valamis is an international technology company specialising in cloud-based digital learning solutions that empower millions of learners, companies, and societies to solve their challenges with transformative learning experiences. Valamis’ end-to-end learning solution includes Valamis’ LXP, LMS, LRS, Content Authoring Lesson Studio, eCommerce, and extensive integrations. Valamis creates long-term value for businesses and their people by being a strategic partner in learning while providing technology and consultancy services in design, data science, technology, corporate performance, and digital learning. Founded in 2003, Valamis is headquartered in Finland and maintains offices in countries around the world.
Learn more about Valamis: Website | YouTube | LinkedIn | Twitter
About TWM
TWM is the most reputable provider of Learning Platforms for clients who have a strategic take on developing their people. Our difference is that our people are former L&D professionals. We always work closely and in partnership with clients, helping solve their problems and providing a platform that we guarantee will do what we say it will.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210722005023/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
